Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia

Author:

Hahn Theresa1,McCarthy Philip L.1,Zhang Mei-Jie1,Wang Dan1,Arora Mukta1,Frangoul Haydar1,Gale Robert Peter1,Hale Gregory A.1,Horan John1,Isola Luis1,Maziarz Richard T.1,van Rood Jon J.1,Gupta Vikas1,Halter Joerg1,Reddy Vijay1,Tiberghien Pierre1,Litzow Mark1,Anasetti Claudio1,Pavletic Stephen1,Ringdén Olle1

Affiliation:

1. From the Roswell Park Cancer Institute, Buffalo, NY; Medical College of Wisconsin, Milwaukee, WI; University of Minnesota, Minneapolis; Mayo Clinic, Rochester, MN; Vanderbilt University, Nashville; St Jude Children's Research Hospital, Memphis, TN; Emory University, Atlanta, GA; Mount Sinai Medical Center, New York, NY; Oregon Health & Science University, Portland, OR; Leiden University Medical Center, Leiden, the Netherlands; Princess Margaret Hospital, Toronto, Ontario, Canada; University Hospital...

Abstract

Purpose Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved. Patients and Methods Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk. Results Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL. Conclusion This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Reference27 articles.

1. Graft-versus-Host Disease and Survival in Patients with Aplastic Anemia Treated by Marrow Grafts from HLA-Identical Siblings

2. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma

3. Jacobsen N, Badsberg HK, Lonnqvist B, et al: Graft-versus leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients: The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 5:413,1990-418,

4. Michallet M, Corront B, Bosson JL, et al: Role of splenectomy in incidence and severity of acute graft-versus-host disease: A multicenter study of 157 patients. Bone Marrow Transplant 8:13,1991-17,

5. RISK FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3